T. Rowe Price Investment Management, Inc. Apellis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 47,713 shares of APLS stock, worth $873,147. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,713
Previous 47,713
-0.0%
Holding current value
$873,147
Previous $1.52 Million
31.45%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$225 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$224 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$218 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$185 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$176 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.01B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...